Skip to main content

Table.1 Clinical characteristics of published cases of Guillain–Barré syndrome/Miller Fisher syndrome following COVID-19 vaccination

From: Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Case No. Age, Sex Symptoms limb weakness Paraesthesia FD OP RF Other neurological signs Diagnosis AGA Comorbidies, Underlying disease Treatment Vaccine type Time to symptom onset Reference No.
1 54,M   + +     GBS negative nothing oral PSL Oxford–AstraZeneca 12 days [5]
2 20,M   + +    headache GBS negative ulcerative colitis oral PSL Oxford–AstraZeneca 21 days [5]
3 57,M + + + +   dysarthria GBS negative asthma, osteoarthritis IVIg Oxford–AstraZeneca 11 days [5]
4 55,M   + +     GBS negative HTN nothing Oxford–AstraZeneca 22 days [5]
5 66,M   + +    tongue numbness, ataxic gait BFP negative n.d. IVIg Oxford–AstraZeneca 7 days [1]
6 43,M    +    neck pain, urinary retention,dysphagia BFP negative n.d. IVIg Oxford–AstraZeneca 11 days [1]
7 51,M   + +    leg pain BFP GM3(+) n.d. nothing Oxford–AstraZeneca 7 days [1]
8 71,F +   +    back pain, abdominal pain, altered taste BFP negative COVID-19 (47 days ago) nothing Oxford–AstraZeneca 12 days [1]
9 53,M   + +    back pain BFP n.d. n.d. nothing Oxford–AstraZeneca 8 days [1]
10 32,M   + +    dysphagia, headache, dysarthria GBS n.d. GBS (14 years ago) IVIg, PP vector-based vaccine 8 days [6]
11 62,F + +    + dysarthria, dysphagia GBS n.d. bronchiectasis, asthma, osteoporosis, migraine IVIg, MV Oxford–AstraZeneca 8 days [7]
12 74,M +   +    back pain, urinary retention, dysarthria AIDP, ITP n.d. HTN, gout, HL, cardiomyopathy IVIg, PP, PSL Moderna 13 days [8]
13 43,F +   +   + back pain GBS n.d. n.d. IVIg, MV Oxford–AstraZeneca 10 days [9]
14 67,F + + +   + dysphagia GBS negative n.d. IVIg, PP, MV Oxford–AstraZeneca 14 days [9]
15 53,F + + +   + tongue numbness, back pain GBS negative n.d. IVIg, MV Oxford–AstraZeneca 12 days [9]
16 68,F + + +   + dysphagia, facial numbness GBS negative n.d. IVIg, MV Oxford–AstraZeneca 14 days [9]
17 70,M   + +   + bulbar palsy GBS n.d. n.d. IVIg, MV Oxford–AstraZeneca 11 days [9]
18 69,F   + + +   bulbar palsy GBS n.d. n.d. IVIg, PP Oxford–AstraZeneca 12 days [9]
19 69,F   + +   + bulbar palsy GBS n.d. n.d. IVIg, MV Oxford–AstraZeneca 13 days [9]
20 60,F   +   +   back and legs pain, headache, vomiting GBS negative migraine IVIg Johnson & Johnson 10 days [10]
21 59,M   + +    postural instability GBS negative HTN, hyperuricemia IVIg Oxford–AstraZeneca 10 days [11]
22 37,M + +     back pain GBS n.d. nothing IVIg Oxford–AstraZeneca 14 days [12]
23 73,M +       GBS n.d. HTN, RA IVIg Pfizer/BioNTech 16 ~ 17 days [4]
24 82,F   +     difficulty walking GBS n.d. nothing IVIg Pfizer/BioNTech 7 days [13]
25 71,M     +   headache, ocular pain, ptosis, ataxia MFS negative DM IVIg Pfizer/BioNTech 18 days our case
  1. GBS Guillain-Barre syndrome, MFS Miller Fisher syndrome, COVID-19 Coronavirus disease 2019, FD Facial diplegia, OP Ophthalmoplegia, RF Respiratory failure, AGA Anti-ganglioside antibodies, GM3 Anti-GM3 antibody, AIDP Acute inflammatory demyelinating polyneuropathy, BFP Bifacial weakness with paraesthesias, ITP Immune thrombocytopenia, HTN Hypertension, DM Diabetes mellitus, RA Rheumatoid arthritis, HL Hyperlipidemia, n.d. No data, MV Mechanical ventilation, PP Plasmaphersis, PSL Prednisolone